

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/109268 A1

(51) International Patent Classification:

A61K 31/472 (2006.01) C07D 221/18 (2006.01)
C07D 217/24 (2006.01)

(21) International Application Number:

PCT/US2021/060088

(22) International Filing Date:

19 November 2021 (19.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/116,727	20 November 2020 (20.11.2020)	US
63/127,928	18 December 2020 (18.12.2020)	US
63/182,741	30 April 2021 (30.04.2021)	US
63/256,393	15 October 2021 (15.10.2021)	US

(71) Applicant: **DENALI THERAPEUTICS INC.** [US/US];
161 Oyster Point Blvd., South San Francisco, California
94080 (US).

(72) Inventors: **BAGDASARIAN, Alex L.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **BUCHER, Cyril**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **CRAIG, II, Robert A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **DE VICENTE FIDALGO, Javier**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **ESTRADA, Anthony A.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **FOX, Brian M.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **HU, Cheng**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **HUFFMAN, Benjamin J.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **LEXA, Katrina W.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **NILEWSKI, Lizanne G.**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **OSIPOV, Maksim**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US). **THOTTUMKARA, Arun**; c/o Denali Therapeutics Inc., 161 Oyster Point Blvd., South San Francisco, California 94080 (US).

(74) Agent: **TANNER, Lorna L.** et al.; SHEPPARD MULLIN RICHTER & HAMPTON LLP, 650 Town Center Drive, 10th Floor, Costa Mesa, California 92626-1993 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: COMPOUNDS, COMPOSITIONS, AND METHODS

(57) Abstract: The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NL-RP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.

WO 2022/109268 A1